[
    {
        "open": "67.260000",
        "high": "67.890000",
        "low": "66.600000",
        "volume": "6508262.000000",
        "overnight_volume": "0.000000",
        "bounds": "regular",
        "market_date": "2025-05-23",
        "average_volume_2_weeks": "11331764.800000",
        "average_volume": "11331764.800000",
        "average_volume_30_days": "11093247.681800",
        "high_52_weeks": "148.150000",
        "high_52_weeks_date": "2024-06-25",
        "dividend_yield": "1.733032",
        "float": "3366072775.790000",
        "low_52_weeks": "57.000000",
        "low_52_weeks_date": "2025-04-21",
        "market_cap": "297603607772.703064",
        "pb_ratio": "15.092500",
        "pe_ratio": "20.177594",
        "shares_outstanding": "4420074376.543934",
        "description": "Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv\u00e6rd, Denmark.",
        "instrument": "https://api.robinhood.com/instruments/2e21c3b3-0015-4661-af59-e2d5741bf55d/",
        "ceo": "Lars Fruergaard J\u00f8rgensen",
        "headquarters_city": "Bagsv\u00e6rd",
        "headquarters_state": "Capital Region",
        "sector": "Health Technology",
        "industry": "Pharmaceuticals: Major",
        "num_employees": 76302,
        "year_founded": 1931,
        "payable_date": "2025-04-08",
        "ex_dividend_date": "2025-03-31",
        "financial_status_indicator": "CA0",
        "financial_status_description": "",
        "symbol": "NVO"
    }
]